The main risk is commercial conversion, not reactor science. NuScale has a credible regulatory asset and useful supplier progress, but 2031 value still hinges on a few external gates: a definitive U.S. anchor agreement, project financing, site-specific approvals, and proof that NuScale keeps enough licensing and lifecycle economics after partners, suppliers, and
dilution take their share.